BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

GenSpera 

9901 IH 10 West
Suite 800
San Antonio  Texas  78230  U.S.A.
Phone: 210-477-8537 Fax: n/a


SEARCH JOBS




Industry
Biotechnology






 Company News
Media Advisory: GenSpera's G-202 HCC Clinical Trial Presentation From 5th Asia-Pacific Primary Liver Cancer Expert (APPLE) Meeting Available 7/22/2014 1:29:19 PM
GenSpera Presents G-202 HCC Clinical Trial Update At 5th Asia-Pacific Primary Liver Cancer Expert Meeting 7/15/2014 9:12:27 AM
Kareg Corporation Initiates Coverage On GenSpera With A Speculative Buy Recommendation 7/14/2014 11:05:08 AM
GenSpera Release: Kareg Corporation Initiates Coverage On Genspera With A Speculative Buy Recommendation 7/14/2014 9:37:46 AM
GenSpera To Present Ongoing HCC Trial Data At APPLE 2014 Congress July 12th In Taipei 7/7/2014 9:14:52 AM
GenSpera 2014 Biotechnology Industry Organization (BIO) International Presentation Available 6/30/2014 9:59:48 AM
GenSpera Releases 2014 Biotechnology Industry Organization (BIO) International Presentation And HCC Clinical Trial Update For G-202 6/25/2014 6:17:37 AM
GenSpera (GNSZ) Releases Updated Corporate Video: "Genspera Has Targeted Its Active Ingredient Thapsigargin To Kill Only The Cells We Select: Cancer" 6/23/2014 8:06:28 AM
GenSpera CEO, Craig Dionne, To Present Update On Lead Drug Candidate G-202 At 2014 Biotechnology Industry Organization (BIO) International Convention 6/19/2014 6:53:59 AM
GenSpera Announces $3.33 Million Registered Public Offering 5/29/2014 9:05:40 AM
12345